MNPR
Monopar Therapeutics·NASDAQ
--
--(--)
--
--(--)
Latest data update time: Updated on 2026-03-28
Latest data update time: Updated on 2026-03-28
7.39 / 10Overall Score
OutperformInvestment Rating
7.39 / 10Overall Score
OutperformInvestment Rating
Is MNPR a Good Buy Right Now?
- Based on a composite score of 7.39/10, we rate MNPR as a Outperform. Our analysis breaks down into 5.08/10 for Fundamentals, 3.62/10 for Technicals, and 10.43/10 for Sentiment, indicating the stock is likely to See further upside.
Technical Analysis of MNPR?
Is MNPR undervalued or overvalued?
Is money flowing into or out of MNPR?
Is MNPR a Good Buy Right Now?
- Based on a composite score of 7.39/10, we rate MNPR as a Outperform. Our analysis breaks down into 5.08/10 for Fundamentals, 3.62/10 for Technicals, and 10.43/10 for Sentiment, indicating the stock is likely to See further upside.
Is MNPR undervalued or overvalued?
Technical Analysis of MNPR?
Is money flowing into or out of MNPR?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
